首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy of Immunotherapy With TG4040, Peg-Interferon,and Ribavirin in a Phase 2 Study of Patients With Chronic HCV Infection
Authors:Adrian M. Di Bisceglie,Ewa Janczweska&ndash  Kazek,Franç  ois Habersetzer,Wlodzimierz Mazur,Carol Stanciu,Vicente Carreno,Coman Tanasescu,Robert Flisiak,Manuel Romero&ndash  Gomez,Alexander Fich,Vincent Bataille,Myew&ndash  Ling Toh,Marie Hennequi,Patricia Zerr,Gé  raldine Honnet,Geneviè  ve Inchauspé  ,Delphine Agathon,Jean&ndash  Marc Limacher,Heiner Wedemeyer
Affiliation:1 Department of Internal Medicine, St. Louis University Liver Center, St. Louis, Missouri;2 Department of Infectious Diseases, Medical University of Silesia, Chorzow, Poland;3 Pôle Hépato-Digestif, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, Strasbourg, France;4 Department of Internal Medicine, Medical University of Silesia, Katowice, Poland;5 Institute of Gastroenterology and Hepatology, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania;6 Foundation for the Study of Viral Hepatitis, Madrid, Spain;7 Internal Medicine Clinic, Colentina Clinical Hospital, Bucharest, Romania;8 Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland;9 Unit for the Clinical Management of Digestive Diseases and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Valme University Hospital, Sevilla, Spain;10 Department of Gastroenterology, Soroka Medical Center, Beersheba, Israel;11 Transgene, Illkirch, France;12 Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
Abstract:
Keywords:Vaccine   ELISpot   Immune Response   SVR24
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号